Barinthus Biotherapeutics PLC Sponsored ADR (NASDAQ:BRNS) Sees Significant Increase in Short Interest

Barinthus Biotherapeutics PLC Sponsored ADR (NASDAQ:BRNS) was the recipient of a significant growth in short interest in the month of June. As of June 30th, there was short interest totaling 44,712 shares, a growth of 102.3% from the June 15th total of 22,107 shares. Based on an average daily volume of 25,828 shares, the days-to-cover ratio is presently 1.7 days. Approximately 0.1% of the shares of the company are short sold.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings raised shares of Barinthus Biotherapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a report on Monday, June 15th. One research analyst has rated the stock with a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the stock has an average rating of “Hold” and an average target price of $4.00.

Institutional Investors Weigh In On Barinthus Biotherapeutics

Several institutional investors and hedge funds have recently added to or reduced their stakes in BRNS. Baird Financial Group Inc. grew its holdings in shares of Barinthus Biotherapeutics by 108.2% during the second quarter. Baird Financial Group Inc. now owns 192,461 shares of the company’s stock worth $179,000 after buying an additional 100,000 shares in the last quarter. Renaissance Technologies LLC boosted its position in Barinthus Biotherapeutics by 115.8% during the fourth quarter. Renaissance Technologies LLC now owns 143,100 shares of the company’s stock worth $100,000 after acquiring an additional 76,800 shares during the last quarter. Finally, Rangeley Capital LLC grew its stake in Barinthus Biotherapeutics by 88.8% during the 1st quarter. Rangeley Capital LLC now owns 159,465 shares of the company’s stock valued at $91,000 after acquiring an additional 75,024 shares in the last quarter. Institutional investors and hedge funds own 25.20% of the company’s stock.

Barinthus Biotherapeutics Trading Down 6.9%

BRNS traded down $0.05 during midday trading on Friday, hitting $0.62. 2,017 shares of the company traded hands, compared to its average volume of 56,155. The company has a market capitalization of $25.49 million, a price-to-earnings ratio of -0.48 and a beta of -0.41. Barinthus Biotherapeutics has a 52-week low of $0.51 and a 52-week high of $2.91. The business has a 50 day simple moving average of $0.67 and a two-hundred day simple moving average of $0.66.

Barinthus Biotherapeutics (NASDAQ:BRNS) last posted its quarterly earnings data on Thursday, April 30th. The company reported ($0.14) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.28) by $0.14.

About Barinthus Biotherapeutics

Barinthus Biotherapeutics plc, a clinical-stage biopharmaceutical company, engages in development of novel T cell immunotherapeutic candidates designed to guide the immune system to overcome chronic infectious diseases, autoimmunity, and cancer. The company's development pipeline includes VTP-300, an immunotherapeutic candidate under phase 2 studies as a potential component of a functional cure for chronic hepatitis B virus (HBV) infection; VTP-200, a non-surgical product candidate under phase 2 studies for treating persistent high-risk human papillomavirus (HPV) infection; VTP-1000, an autoimmune preclinical candidate designed to treat patients with celiac disease; VTP-1100 product candidate to target HPV16+ cancers; and VTP-850/850, a second-generation immunotherapeutic candidate under phase 2 studies to treat recurrent prostate cancer.